Rx Direct Access
As the cost and demand for GLP-1 medications for weight loss exponentially rises, employers are looking for ways to make covering these drugs more affordable and predictable. Our 2025 Best Practices in Healthcare Survey shows that 48% of employers are covering GLP-1 medications for weight loss (78% cite lower medication costs as a factor in their coverage decisions). With net annual costs of $7,000 to $8,000 per user, many employers are taking a hard look at how to provide affordable and reasonable access to GLP-1 drugs for weight loss. For 6% of employers, the costs have become unsustainable, and they have made the decision to remove coverage of GLP-1s for obesity. Another 9% of employers are considering similar action by 2027.
This is where our new solution, Rx Direct Access, can help. We’ve initially partnered with Virta and RxSaveCard to develop an innovative direct-to-patient approach for GLP-1 weight loss prescriptions. This way, these prescriptions are excluded from standard formulary and benefit structures. This approach involves Virta clinicians determining the appropriate treatment journeys for members.
Key benefits
The Virta program offers several benefits for plan sponsors and members:
- Clinical wrap: Virta clinicians and health coaches support members, ensuring proper use, side effect management and adherence
- Transparent consumer pricing: Eliminates rebates by providing transparent pricing
- Lower costs: Offers lower prices compared to typical payer prices of $700–800 per script (net of rebates)
- Flexibility: Allows for flexible member cost-sharing arrangements
- Potential savings: Provides potential savings and trend mitigation for plan sponsors
Partnership and support
Through Rx Direct Access, we’ve partnered with Virta and RxSaveCard to offer a subsidy program for members. We provide opportunity assessment and outcomes analysis to bring this solution to life.
This collaborative approach ensures that members receive the support they need. Plan sponsors can benefit from transparent, predictable pricing through a funding mechanism, alongside clinical journey support for members.